More effective than LM25 in certain dietary conditions, including with increased carbohydrate
WEDNESDAY, June 22, 2016 (HealthDay News) — For East Asian patients with type 2 diabetes, 50 percent insulin lispro/50 percent insulin lispro protamine (LM50) is more efficacious as starter insulin than 25 percent insulin lispro/75 percent insulin lispro protamine (LM25), according to a study published online June 8 in the Journal of Diabetes Investigation.
Wei Chen, from the Peking Union Medical College Hospital in Beijing, and colleagues examined the effect of diet on the efficacy of LM25 and LM50 as starter insulin in 328 Chinese and Japanese patients with type 2 diabetes in a predefined subgroup analysis of a phase 4 trial. Participants were randomized to receive twice-daily LM25 (168 patients) or LM50 (160 patients). Food records kept by subjects before study drug administration were used to assess nutritional intake.
The researchers found that regardless of nutritional intake, improvements in self-monitored blood glucose were significantly greater in the LM50 group than the LM25 group (P ≤ 0.028). LM50 was significantly more efficacious than LM25 in improving 1,5-anhydroglucitol and glycated hemoglobin when carbohydrate (by weight or percentage energy) or fat (by weight) intake exceeded median levels (P ≤ 0.026).
“Glycemic control improved in both LM25 and LM50 groups, but LM50 was significantly more efficacious under certain dietary conditions, particularly with increased carbohydrate intake,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures insulin lispro and funded the study.
Copyright © 2016 HealthDay. All rights reserved.